Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.534

+8.4%

3:37 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who started this subject	9/26/2000 9:48:45 AM
From: nigel bates	of 368

Sept. 26 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - news) and Rosetta Inpharmatics, Inc. (Nasdaq: RSTA - news) today announced that they intend to apply their complementary technologies in gene regulation and informational genomics to perform functional genomic studies on potential therapeutic targets. The research is intended to better understand the role of certain genes or proteins that may be promising candidates for therapeutic drug development. Each company will fund their respective efforts. Using its proprietary Rosetta Resolver(TM) software platform, Rosetta has been able to identify particular genes as functioning within specific biological pathways. Sangamo expects to use this information to design and build engineered transcription factors able to regulate the expression of specific genes. Utilizing Sangamo's Universal GeneTools(TM) reagents targeted to these genes, Rosetta may be able to directly assess the role that specific proteins play in a disease process. The combination of these technologies can potentially help determine whether these proteins are good ``targets'' for drug development. ``Our relationship with Rosetta is a great example of how two unique yet complementary technologies may be combined to streamline the process of drug development,'' said Edward Lanphier, Sangamo's president and chief executive officer. ``Once these targets are identified, we are one important step closer to developing effective new therapeutics.'' ``The ability to regulate the function of specific genes using Sangamo's technology can provide important reference points to understand disease pathways and the effects of specific compounds,'' noted Stephen Friend, M.D., Ph.D., president and chief executive officer of Rosetta Inpharmatics...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next